SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
Positive
interim data from consumer participant study for Acne
27 February
2024 - SkinBioTherapeutics
plc (AIM: SBTX), a life science company focused on skin health,
announces that interim data from the AxisBiotix Acne food
supplement consumer participant study with the lead formulation are
very positive. The Company will continue the study to completion.
The analysis and read-out of the final results is anticipated to
occur before the end of Q1 2024.
The volunteer study, comprising 220
people, followed the same methodology to the AxisBiotix-Ps study,
with the supplement containing the lead formulation, being supplied
to participants in powder-form. Participants were then asked to
record scores against specific criteria on an app. The scoring
criteria included severity of acne, level of pain, attitude to
appearance and levels of confidence.
The full study length is 56 days to
reflect the time it takes for the skin to replenish itself
completely. In people, the number of days ranges from 40-56 days,
depending on age and location, therefore the maximum time was
chosen for the study.
Interim study results
|
Criteria and questions
|
Week 1
|
Week 5
|
|
Severity of acne: How do you
rate your spots on a scale of 1-10, with 10 being the most
severe
|
71%
(score 4 or more)
|
37%
(score 4 or more)
|
|
Pain of acne spots: Are your
spots painful? On a scale of 1 - 10, with 10 being the most
concern
|
64%
(score 4 or more)
|
43%
(score 4 or more)
|
|
Concern over appearance: How
concerned are you about the effect your spots have on your
appearance? On a scale of 1 - 10, with 10 being the most
concern
|
94%
(score 4 or more)
|
56%
(score 4 or more)
|
|
Level of self-confidence: Do
you worry about going out in public because of your spots? On a
scale of 1 - 10, with 10 being the most concern
|
84%
(score 4 or more)
|
47%
(score 4 or more)
|
While results at this interim point
are positive, there can be no certainty that these will either
improve or be maintained. The completion of the full study
and analysis of the total data set is required to understand the
outcomes.
The study is being conducted by an
independent third-party, and the supplement blend has been
formulated and manufactured by the Dutch food supplement provider
Winclove Probiotics BV.
Stuart Ashman, CEO of SkinBioTherapeutics
Plc, said:
"We are really excited to see such positive results against
all the criteria at this interim stage. After the success of
running a consumer participant study with the AxisBiotix-Ps
product, we followed the same set-up for our acne candidate. And,
just like the AxisBiotix study, many participants have recorded
quite dramatic changes in their condition already. We have another
three weeks to go, but if the final results reflect similar levels
of effectiveness, we have the potential for a really important, new
and effective option for people with acne of all
ages."
Up to 85% of people will suffer from
acne at some point in their life and sufferers tend to be keen to
alleviate their symptoms. The global acne market is worth
$9.4billion with CAGR of 4.8% (Fortune Business Insights 2019). In
the UK alone, the market is worth c. £250m in 2022 and is projected
to reach c.£300m in 2030, with c.34% of adults in the UK
experiencing acne at some time in their lives. Acne is the most
common skin condition and one of the top 10 most prevalent diseases
worldwide.
Although not life-threatening, acne
can cause irritation and life-long scarring, and can negatively
impact a person's mental health and self-esteem. Acne develops when
pores get clogged with dead skin, bacteria, and dried skin oil
buildup, which leads to redness, tenderness, pimples, nodules, or
cysts primarily on the face, back, or chest.
Acne can range from mild to severe
and typically affects teenagers and young adults but anyone can be
affected. Treatment of severe acne often requires topical steroid
creams which can lead to undesirable side effects, including skin
dryness, irritation, and rashes. Alternative treatments include
oral medications where side effects can be more severe e.g.
depression or suicidal thoughts.
-Ends-
The information communicated in this announcement contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) No. 596/2014.
|
For
more information please contact:
|
SkinBioTherapeutics plc
Stuart J. Ashman, CEO
Manprit Randhawa, CFO
|
Tel: +44 (0) 191 495
7325
|
|
Cavendish Capital Markets Limited
(Nominated Adviser & Broker)
Giles Balleny, Dan Hodkinson
(Corporate Finance)
Charlie Combe (Broking)
Dale Bellis, Tamar Cranford-Smith
(Sales)
|
Tel: +44 (0) 20 7220
0500
|
|
Instinctif Partners (financial press)
Melanie Toyne-Sewell / Jack
Kincade
|
Tel: +44 (0) 20 7457
2020
SkinBioTherapeutics@instinctif.com
|
|
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life
science company focused on skin health. The Company's proprietary
platform technology, SkinBiotix®, is based upon
discoveries made by Professor Catherine O'Neill and Professor
Andrew McBain.
The Company is targeting a number of
skin healthcare sectors, the most advanced of which are cosmetic
skincare and food supplements to modulate the immune system by
harnessing the gut-skin axis. In each area SkinBioTherapeutics
plans to exemplify its technology through human studies. The
Company's first product, AxisBiotix-Ps™, a food supplement to
address the symptoms of mild to moderate psoriasis.
The Company listed on AIM in April
2017 and is based in Newcastle, UK. For more information,
visit: www.skinbiotherapeutics.com and
www.axisbiotix.com.
